33 results about "Heart muscles" patented technology

The present invention belongs to the technical field related to cardiac monitoring, and discloses a passive sensor for real-time cardiac monitoring and its application. The passive sensor includes a monitoring unit, a flexible substrate, and a signal receiving unit, wherein: the monitoring unit is a thin film composed of a material with an electric double layer effect. Thus, cations and anions in the interstitial fluid around the heart are adsorbed on the surface of the monitoring unit to form an electric double layer structure. When the cardiac muscle relaxes and contracts or the blood flow signal is transmitted, the change in pressure will further cause the change in the effective charge adsorption area, resulting in the change of the current signal; the flexible substrate is used to isolate the monitoring unit and the signal receiving unit; the signal receiving unit is connected to the monitoring unit for receiving the charge change on the surface of the monitoring unit, and serves as a counter electrode to form a closed loop with the monitoring unit. This application can realize the real-time monitoring and signal acquisition of cardiac mechanical signals, with high sensitivity and high accuracy.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

A device for use during cardiothoracic surgery around the heart of a patient. The device includes an angled drainage tube including a first portion having a plurality of drainage orifices and a second portion which is angled relative to the first portion. A flexible drainage tube extends from the angled tube and is in fluid communication therewith. A pair of pacing electrodes are disposed on a single aspect of the first portion of the angled drainage tube. The pacing electrodes are adapted to be in contact with the heart muscle for intrinsic rhythm sensing and pacing capability thereof. At least one electrical wire is connected to the pacing electrodes and extends along a portion of the angled drainage tube. The at least one electrical wire is connectable to a pacing box via a cable for powering and controlling the pacing electrodes.

Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, for example, large volume muscle loss, including skeletal and heart muscle, blast wave injury, muscle loss from diabetes and resulting from frailty as a result of aging.

A system and method for monitoring a patient's blood flow waveform require a pulse oximeter to non-invasively measure changes in parametric and blood flow measurements of the waveform. These parametric measurements, namely changes in diastolic pressure, ±Δpd, changes in systolic pressure, ±Δps, and changes in pulse time rate, ±Δtr, collectively affect the patient's blood flow volume. Thus, they can also be used, collectively, to assess the patient's heart muscle function as an indicator of his / her health condition.

Methods, systems, and apparatuses for treating a heart are provided. Methods can include obtaining and using an implant. One or more catheters can be used to properly position and attach the implant in a desired location in a chamber of the heart, for example, such that (i) a first portion of the implant is anchored to a first site on a wall of the chamber, (ii) a second portion of the implant is anchored to a second site on the wall of the chamber, (iii) a mid-portion of the implant extends in a curved path along the wall of the chamber between the first site and the second site, and (iv) an elongate contraction member of the implant cuts across the chamber between the first site and the second site. Other embodiments are described.

The invention relates to the technical field of heart electrophysiological information analysis, in particular to a data analysis system and method based on three-dimensional heart modeling, and the method comprises the steps: obtaining a heart three-dimensional medical image, reconstructing a heart muscle grid, constructing a public heart coordinate, and dividing the surface of an endocardium into a plurality of endocardium partitions; fusing catheter mapping points and local potential waveforms on the geometric model, establishing a three-dimensional electrophysiological propagation model consistent with individual anatomy, and forming heart digital twinning; a structural network and a propagation network are constructed based on endocardium partition, an excitation propagation path and a turn-back risk are analyzed, and influences of different targets on the turn-back risk are compared through virtual ablation simulation, so that a quantitative basis is provided for myocardial ablation target selection and intervention strategy formulation.

A device for use during cardiothoracic surgery around the heart of a patient. The device includes an angled drainage tube including a first portion having a plurality of drainage orifices and a second portion which is angled relative to the first portion. A flexible drainage tube extends from the angled tube and is in fluid communication therewith. A pair of pacing electrodes are disposed on a single aspect of the first portion of the angled drainage tube. The pacing electrodes are adapted to be in contact with the heart muscle for intrinsic rhythm sensing and pacing capability thereof. At least one electrical wire is connected to the pacing electrodes and extends along a portion of the angled drainage tube. The at least one electrical wire is connectable to a pacing box via a cable for powering and controlling the pacing electrodes.

System and methods for monitoring and / or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.

Circuitless heart rhythm determination can include capturing a video clip of one or more image frames of a target organ through an ultrasound imaging device and submitting the frames to a classifier that has been trained with an annotated set of images, each of a corresponding heart muscle captured at a specified phase of a heart rhythm with a ground truth indication of the specified phase of the heart rhythm drawn from a separately recorded cycle graph of an electrical signal measured over time for the corresponding heart muscle. In response to the submission, a classification can be received of different portions of the submitted frames according to corresponding phases of the heart rhythm. Finally, a contemporaneous phase of the heart rhythm can be determined in the device without sensing electrical signals by way of a closed-loop sensor circuit affixed proximately to the target heart muscle.

The present disclosure relates to an implantable device for improving the pump function of the heart of a human patient by applying an external force on the heart muscle. The device is provided with a first part having a first surface comprising a ceramic material, and a second part having a second surface comprising a ceramic material.

The garment suitable for hosting a management and functioning logic and sensors / electrodes positioned in predetermined areas of the human body suitably is stabilized by the innovative characteristics of the garment itself and aimed at visualizing the state of health of the heart muscle. The sensors feature a new type of layout in order to minimize artifacts during vectorcardiogram generation. The entire apparatus communicates in real time with the Internet and exploits the architectures of Artificial Intelligence in order to improve the predictive performance of any heart disease.

The present invention relates to an animal heart - simulated uterus containing a presser. The simulated uterus includes a presser and a primary uterine mold. The presser includes an upper mold and a lower mold. The primary uterine mold is made from an animal heart and has a cavity structure with an open lower end. The outer wall of the primary uterine mold fits against the inner wall of the presser. One end of the primary uterine mold is provided with a uterine orifice. The part of the primary uterine mold that fits against the upper opening is the uterine horn, and the part of the primary uterine mold between the two uterine horns is the uterine fundus. The part of the primary uterine mold from the uterine orifice to the uterine horn is successively the cervix and the uterine body. The method for preparing the simulated uterus at least includes: selecting a biological tissue material, performing pretreatment, putting it into the presser and cutting off the excess animal heart muscle outside the presser, and aligning the upper mold with the lower mold. By preparing this animal heart - simulated uterus, an anatomical model of a simulated uterus is constructed, and at the same time, the simulated uterus can withstand a certain pressure for uterine cavity inflation during hysteroscopic surgery, ensuring the normal progress of simulated hysteroscopic surgery.

The invention relates to an application of D-ribose in a cumulative exercise fatigue subject, which is beneficial to improving and / or protecting the myocardial function of the subject, improving the myocardial hypoxia tolerance of the subject, improving and / or protecting the skeletal muscle function of the subject, reducing the inflammation occurrence risk of the subject, and improving the exercise performance ability and exercise tolerance of the subject. And / or accelerating exercise fatigue recovery.

A method for manufacturing a multilayer engineered heart muscle that includes (i) providing a liquid reconstitution mixture in a mould and (ii) culturing the mixture. The method includes a sequential addition of one or more further liquid reconstitution mixtures to obtain a multilayer engineered heart muscle. The muscle ideally has the form of a patch, a pouch, or a cylinder. Furthermore, a multilayer engineered heart muscle having collagen, cardiac myocytes and non-myocytes originating from at least 2 layers is disclosed. The multilayer engineered heart muscle forms the basis for several in vitro and in vivo applications such as the production of a multilayer engineered heart muscle for use in a patient, for example for use in heart repair.

The present invention relates to methods for assessing heart muscle tissue damage. The methods are based on the determination of the biomarker MyL7 in a sample from a subject. Moreover, the present invention relates to the use of the biomarker MyL7 (Myosin regulatory light chain 2, atrial isoform) or of at least one detection agent which specifically binds to said biomarker in at least one sample from a subject for assessing heart muscle tissue damage. The present invention further relates to a kit for assessing heart muscle tissue damage.

This invention generally relates to the field of somatic gene therapy by using viral vectors, and in particular adeno-associated virus (AAV) vectors for the treatment of inherited or acquired diseases. More specifically, the invention relates to a viral capsid protein that provide for a specific transduction of murine endothelial cells for treating or preventing a heart disease in a primate. The viral capsid protein was found to specifically bind to primate heart tissue cells, and in particular primate heart muscle cells, and can be used to provide for an efficient and selective transduction of primate cardiomyocytes and ensure heart tissue-specific expression of one or more transgenes in the primate. The invention further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid with at least one transgene packaged in the capsid. The viral vector is suitable for the therapeutic treatment of a cardiac disorder or disease in a primate. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.

The present invention relates to an implantable device for improving the pump function of the heart of a human patient by applying an external force on the heart muscle. The implantable device comprises at least one implantable pump device comprising: A fluid, A first reservoir having a first volume and at least one movable wall portion, for varying said first volume, and A second reservoir being in fluid connection with said first reservoir. Wherein said implantable pump device is adapted to allow free flow of fluid between said first reservoir and said second reservoir, and wherein said first reservoir, said second reservoir and said fluid connection forms a fully implantable closed pump device, and wherein said fully implantable closed pump device is adapted to transfer force from said first reservoir to said second reservoir.

Devices and systems as described herein is configured to sense a signal, such as a signal from an individual. In some embodiments, a signal is a magnetic field. In some embodiments, a source of a signal is an individual's organ, such as a heart muscle. A device or system, in some embodiments, comprises one or more sensors, such as an array of sensors configured to sense the signal. A device or system, in some embodiments, comprises a shield or portion thereof to reduce noise and enhance signal collection.

System and methods for monitoring and / or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.

Aspects of the invention can include a method of preventing and treating disorders caused by myocardial ischemia (obstructed blood flow to the heart muscle), and a method of recovering from the same by administering an effective amount of a pharmaceutically acceptable composition of N,N-Dimethyltryptamine ((DIMETHYLTRYPTAMINE)) or its analogs thereof. Aspects of the invention can also include a method of preventing and treating myocardial ischemic reperfusion injuries during conditions resulting from inadequate blood flow to the heart muscle, and a method of recovering from the same by administering an effective amount of a pharmaceutically acceptable composition of N,N-Dimethyltryptamine ((DIMETHYLTRYPTAMINE)) or an analog thereof.

Various methods and systems for medical imaging systems are provided. In one embodiment, a method includes generating a cardiac ultrasound image from ultrasound imaging data of a heart, generating a spatiotemporal map of electrical impulses in the heart based on contractions and elongations of heart muscle depicted in the cardiac ultrasound image, and outputting the spatiotemporal map of electrical impulses in the heart to a display device. In this way, the spatiotemporal map of electrical impulses in the heart can visually indicate electrical conduction pathways through the heart.

The invention provides methods for predicting whether compounds are cardiotoxic by analyzing their effects on the ratios of concentrations of metabolites in cultured heart muscle cells.

The present invention relates to a myocardial spectrometer probe, comprising: at least two separate light guides (120A, 120B), insertable in a tissue, wherein a first light guide (120A, 120B) is arranged to deliver light and a second light guide (120A, 120B) is arranged to collect light, and wherein the first light guide (120A, 120B) and the second light guide (120A, 120B) are arranged distinct to each other.

The invention specifically discloses a myocardial targeting nanoparticle loaded with lycium barbarum polysaccharide as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The invention provides a myocardial targeting nanoparticle. The myocardial targeting nanoparticle comprises mesoporous polydopamine, lycium barbarum polysaccharide and myocardial targeting peptide. And an effective and accurate treatment strategy is provided for myocardial injury caused by EHS. The work not only provides a promising nano platform for the treatment of heart pathology, but also opens up a wide way for the clinical conversion of targeted therapy of EHS and related diseases.

The invention provides an application of a rhizoma polygonati aqueous extract in preparation of a product for relieving cardiac myocardial injury caused by semeglutide, provides a new application of the rhizoma polygonati aqueous extract, and can effectively relieve the problem of myocardial muscle area reduction caused by semeglutide treatment. When the rhizoma polygonati aqueous extract is used together with the simeglutide, the rhizoma polygonati aqueous extract has the characteristics of not influencing the weight-losing effect and the fat-reducing effect, also has protection and repair effects on cardiac muscle, has dual effects of keeping the fat-reducing effect and relieving myocardial injury, and provides an effective auxiliary scheme for safe use of the simeglutide.

A method for replacement of a defective heart valve involves introducing a distal loop-shaped element of a medical device between the heart muscle wall and chordae of the heart, positioning a first loop-shaped element of the medical device on a first side of the heart valve, arranging the first loop-shaped element to reposition the chordae towards a center of the heart valve, and moving a prosthetic valve along the medical device into position for attachment.

The present invention relates to adeno-associated viral vector delivery of muscle-specific minimal muscular dystrophy proteins for the treatment of muscular dystrophy. The present invention provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, that express miniaturized human Muscle Dystrophin genes, and methods of using these vectors to express minor muscular dystrophy proteins and to protect muscle fibers from damage, increase muscle strength, and reduce and / or prevent fibrosis in subjects suffering from muscular dystrophy in skeletal muscles, including septal and cardiac muscles.

The present invention relates to a device for manually performing anastomosis between a graft vessel and a target vessel in order to bypass the blocked in coronary artery to restore adequate blood flow to the heart muscle. The manually operated configuration of the anastomosis device includes a handle (105) positioned at its distal end and an end-effector assembly (101) positioned at its proximal end. A shaft (103) one end is coupled to the handle (105) and the shaft (103) other end is coupled to the end-effector assembly (101). Further, a cable (223) is positioned within the shaft (103), wherein the cable (223) one end is secured to the handle (105) and the cable (223) other end is secured to the end-effector assembly (101) and the cable (223) facilitates in actuation of the end-effector assembly (101) to perform anastomosis.